Nanjing Yuanpeptide Biotechnology

Nanjing Yuanpeptide Biotechnology is a specialized biopharmaceutical company dedicated to the discovery and development of innovative peptide-based medicines. Headquartered in Nanjing, China, the company utilizes a proprietary technology platform for the structural optimization and modification of peptides to improve their metabolic stability and therapeutic half-life. Their research and development efforts are primarily focused on high-growth therapeutic areas, including metabolic diseases such as obesity and type 2 diabetes, as well as targeted therapies for oncology. The company's pipeline includes next-generation long-acting peptide agonists and peptide-drug conjugates (PDCs) aimed at providing more effective and convenient treatment options for patients. By integrating computational design with advanced chemical synthesis, Nanjing Yuanpeptide Biotechnology seeks to overcome the traditional limitations of peptide drugs, such as rapid degradation and poor oral bioavailability.